Immune response induced by Omicron effectively neutralise Delta: ICMR study

An ICMR study has demonstrated that individuals infected with Omicron have significant immune response which could neutralise not only the Omicron, but also other variants of concern

coronavirus
Press Trust of India New Delhi
2 min read Last Updated : Jan 26 2022 | 4:54 PM IST

An ICMR study has demonstrated that individuals infected with Omicron have significant immune response which could neutralise not only the Omicron, but also other variants of concern, including the most prevalent Delta variant.

It suggests that the immune response induced by the Omicron could effectively neutralise the Delta variant, making the re-infection with Delta variant less likely, thereby displacing the Delta as dominant strain, the study said emphasising upon the need for Omicron-specific vaccine strategy.

The study was conducted on 39 individuals, of which 25 had taken both the doses of AstraZeneca COVID-19 vaccine, eight people had taken double dose of Pfizer jab, while six were unvaccinated.

Also, 28 of these 39 were mainly foreign returnees from the UAE, South/West/East Africa, Middle East, the US and the UK, and 11 people were their high-risk contacts. All these individuals were infected with Omicron variant.

The study assessed the IgG antibody and Neutralizing Antibody (NAb) response in the people with breakthrough and natural COVID-19 infections.

"Our study demonstrated substantial immune response in the individuals infected with Omicron. The neutralizing antibodies could effectively neutralize the Omicron and other variants of concern (VOCs), including the most prevalent Delta variant," the study stated.

The main limitation of this study are lesser participants in the unvaccinated group and the shorter window period post infection. This could be the important reason for the low immune response specifically in the unvaccinated individuals against Omicron, the scientists stated.

The study has been conducted by ICMR scientists, including Pragya D Yadav, Gajanan N Sapkal, Rima R Sahay and Priya Abraham. It is yet to be peer-reviewed and has been released on bioRxiv preprint server on January 26.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusOmicronDelta variant of coronavirusCoronavirus TestsICMR

First Published: Jan 26 2022 | 4:54 PM IST

Next Story